 Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set for April 14, 2022, for the potential approval of vutrisiran for the treatment of patients with ATTR with polyneuropathy. 